VIADERMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0074 USD | -12.94% |
|
-20.43% | -30.19% |
| 2023 | ViaDerma, Inc. Announces FDA Registration Application Update & Brand Name for New Hair Regrowth Product | CI |
| 2023 | ViaDerma Announces Intent to Launch New Minoxidil Hair Regrowth Product | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2015 | 192K 16.01M | Sales 2016 | 252K 21.03M | Capitalization | 618K 51.6M |
|---|---|---|---|---|---|
| Net income 2015 | - 0 | Net income 2016 | - 0 | EV / Sales 2015 | 1.5 x |
| Net Debt 2015 | 288K 24.06M | Net Debt 2016 | 297K 24.77M | EV / Sales 2016 | 3.63 x |
| P/E ratio 2015 |
10.7
x | P/E ratio 2016 |
-3.3
x | Employees | 75 |
| Yield 2015 * |
-
| Yield 2016 |
-
| Free-Float | 99% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -12.94% | ||
| 1 week | -20.43% | ||
| Current month | -23.71% | ||
| 1 month | -32.11% | ||
| 3 months | -19.57% | ||
| 6 months | -38.84% | ||
| Current year | -30.19% |
1 week
0.01
0.01
1 month
0.010.01
Current year
0.010.02
1 year
0.010.02
3 years
0.000.06
5 years
0.000.08
10 years
0.000.51
| Managers | Title | Age | Since |
|---|---|---|---|
Chris Ayo Otiko
CEO | Chief Executive Officer | - | 31/14/31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chris Ayo Otiko
CEO | Chief Executive Officer | - | 31/14/31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/24/14 | 0.0074 | -12.94% | 6,336,610 |
| 13/24/13 | 0.0085 | -1.16% | 1,473,345 |
| 10/24/10 | 0.0086 | -6.45% | 854,118 |
| 09/24/09 | 0.009193 | -1.15% | 1,839,724 |
| 08/24/08 | 0.0093 | 0.00% | 1,048,601 |
Delayed Quote OTC Markets, May 15, 2024 at 01:22 am IST
More quotes
ViaDerma, Inc. is a specialty pharmaceutical company engaged in bringing new products to market and licensing its transdermal drug delivery technology solutions. The Companyâs lead product is a topical antibiotic, which is focused on being sold under the brand name Vitastem. In addition to licensing its proprietary transdermal technologies, its lead product, Vitastem, is available for treating multiple skin conditions and ailments. The Company also has products in development in fields, such as anti-aging skin care, pain management, hair-loss, and toenail fungus. The products are based on a delivery system technology that allows for rapid mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide immediate localized therapy. The Companyâs products are sold to local medical practitioners and patients in clinics primarily in the Los Angeles, California area. The Companyâs subsidiary is ViaDerma, II Inc.
| 1st Jan change | Capi. | |
|---|---|---|
| -30.19% | 10.49M | |
| +29.03% | 48.16B | |
| -0.10% | 41.73B | |
| +43.45% | 41.03B | |
| -5.26% | 28.77B | |
| +11.48% | 25.59B | |
| -22.74% | 18.96B | |
| +9.06% | 12.92B | |
| +30.01% | 12.03B | |
| -1.51% | 11.77B |
- Stock Market
- Equities
- VDRM Stock